GENENTECH, INC.
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration
- First Posted Date
- 2022-03-29
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT05300724
- Locations
- 🇺🇸
New England Retina Consultants, Springfield, Massachusetts, United States
🇺🇸Retina Specialists, DeSoto, Texas, United States
🇺🇸San Antonio Eye Center, San Antonio, Texas, United States
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
- First Posted Date
- 2022-02-17
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05243342
- Locations
- 🇪🇸
Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
🇦🇺Alfred Hospital, Melbourne, Victoria, Australia
🇩🇰Sygehus Lillebælt, Vejle, Vejle, Denmark
Long-Term Follow-Up Study of Risdiplam in Participants With Spinal Muscular Atrophy (SMA)
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT05232929
- Locations
- 🇺🇸
Barrow Neurological Institute, Phoenix, Arizona, United States
🇺🇸Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 218
- Registration Number
- NCT05224102
- Locations
- 🇺🇸
NJ Retina - Teaneck, Teaneck, New Jersey, United States
🇺🇸Barnet Dulaney Perkins Eye Center, Mesa, Arizona, United States
🇺🇸Win Retina, Arcadia, California, United States
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05207670
- Locations
- 🇺🇸
Infirmary Cancer Care, Mobile, Alabama, United States
🇺🇸Alaska Oncology & Hematology, LLC, Anchorage, Alaska, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
A Study of MTPS9579A in Participants With Refractory Chronic Spontaneous Urticaria
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Genentech, Inc.
- Registration Number
- NCT05129423
A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2021-09-08
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 1440
- Registration Number
- NCT05037929
- Locations
- 🇳🇿
Aotearoa Clinical Trials Trust, Auckland, New Zealand
🇺🇸SEC Clinical Research LLC - Dothan 2 - ClinEdge - PPDS, Dothan, Alabama, United States
🇺🇸Jasper Summit Research LLC, Jasper, Alabama, United States
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2021-06-02
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 126
- Registration Number
- NCT04910568
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸City of Hope - Lennar Foundation Cancer Center, Irvine, California, United States
🇺🇸Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center, Denver, Colorado, United States
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration(nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
- Conditions
- Interventions
- First Posted Date
- 2021-04-21
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 188
- Registration Number
- NCT04853251
- Locations
- 🇺🇸
Arizona Retina and Vitreous Consultants, Phoenix, Arizona, United States
🇺🇸California Retina Consultants., Bakersfield, California, United States
🇺🇸Macula Retina Vitreous Center, Torrance, California, United States
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
- Conditions
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT04835805
- Locations
- 🇩🇪
Universitätsklinikum Würzburg, Würzburg, Germany
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Memorial Sloan Kettering, New York, New York, United States